Last reviewed · How we verify

Complicated Genitourinary Tract Infection — Treatment Landscape & Competitive Intelligence

Complicated Genitourinary Tract Infection (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Complicated Genitourinary Tract Infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Recarbrio RELEBACTAM Merck & Co. Renal Dehydropeptidase Inhibitor [EPC] 2019-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 2 drugs in Complicated Genitourinary Tract Infection
  2. Merck & Co. · 1 drug in Complicated Genitourinary Tract Infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Complicated Genitourinary Tract Infection:

Cite this brief

Drug Landscape (2026). Complicated Genitourinary Tract Infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/complicated-genitourinary-tract-infection. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing